ANKTIVA was approved by the FDA in 2024 with BCG for the treatment of BCG unresponsive NMIBC with Papillary tumors with CIS (Cohort A). In the same clinical trial (QUILT-3.032) long term results of ...
Okay. Good morning, everyone. The 2025 Annual Meeting of Stockholders of Texas Instruments Incorporated is hereby called to order. I’m Rich Templeton, Chairman of the Board of Directors. Our meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback